NOD 800
Alternative Names: NOD-800Latest Information Update: 01 Apr 2021
At a glance
- Originator Nanoscope Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Eye protein replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Dry age-related macular degeneration
Most Recent Events
- 19 Mar 2021 Nanoscope Therapeutics files for patent protection with for Nano enhanced optical delivery of exogenous molecules to cells and tissues worldwide
- 19 Mar 2021 Preclinical trials in Dry age-related macular degeneration in USA (Ophthalmic) prior to March 2021 (Nasoscope Therapeutics pipeline, March 2021)